Premenstrual syndrome (PMS) affects...

Premenstrual syndrome (PMS) affects millions of women during their reproductive years. The disorder is characterized by dint of the cyclic recurrence of symptoms during the luteal phase of the menstrual period (Table 1). (1-3) Symptoms typically begin between the ages of 25 and 35 years. Women who have bitter affective symptoms may also suited criteria for premenstrual dysphoric disorder (PMDD) In the pair PMS and PMDD, symptoms diminish rapidly with the attack of menses.

Up to 85 percent of menstruating women report having united or more premenstrual symptoms, and 2 to 10 percent report disabling, incapacitating symptoms. (45) More than 200 symptoms have been associated with PM on the other hand irritability, tension, and dysphoria are the greatest in quantity prominent and consistently described. (5)

The management of PM is many times frustrating for both patients and physicians. Clinical issues can be expected to improve as a terminate of recent consensus on diagnostic criteria for PM and PMDD data from improved clinical trials, and the availability of evidence-based clinical guidelines.

Etiology

The etiology of PM remains unknown and may be entangled and multifactorial. The role of ovarian hormones is unclear, still symptoms often improve when ovulation is destroyed (6) Changes in hormone plains may influence centrally acting neurotransmitters like as serotonin, (1) but circulating sex hormone horizontals are typically normal in women with PM more [i]or[/i] less evidence suggests that the disorder is related to enhanced sensitivity to progesterone in women with underlying serotonin deficiency. (147) This mechanism may not explain all cases, because about patients do not respond to treatment with selective serotonin reuptake inhibitors (SSRIs). (8) Deficiencies in prostaglandins, related to an inability to change the heart of linoleic acid to prostaglandin precursors, may be involved in PMS29 Genetic factors also look to play a role, as the concordance rate is sum of two units times higher in monozygotic twins than in dizygotic twins. (10)

Diagnosis

The American community of Obstetrics and Gynecology (ACOG) make acceptables the PMS diagnostic criteria bring to maturityed by the University of California at San Diego and the National Institute of Mental Health (Table 2) (47) In women with plain dysphoric symptoms and significant dysfunction, research criteria can be used to establish the diagnosis of PMDD (Table 3) (11) All diagnostic criteria emphasize the periodicity and severity of symptoms.

PM and PMDD can solitary be diagnosed after a variety of physical and psychiatric disorders have been exclud (Table 4) (34) PM also must be distinguished from simple premenstrual symptoms (eg bloating, breast tenderness) that do not interfere with daily functioning and are characteristic of normal ovulatory revolution of times (7) (Figure 1). The three key-note elements of the diagnosis are symptoms consistent with PM consistent casualty of symptoms only during the luteal phase of the menstrual period and negative impact of symptoms onward function and lifestyle. (4)

[FIGURE 1 OMITTED]

When PM or PMDD is suspected, patients should be instructed to retain a premenstrual daily symptom diary for several consecutive month in like manner that cycle-to-cycle variability can be examined (Figure 2) Based in succession this diary, many women may be originate to have nonluteal symptom patterns. (7) Standardized daily symptom calendars, like as the Calendar of Premenstrual Experiences and the Prospective Record of the Impact and Severity of Menstruation, provide reliable and convenient records. (47)

Management

Treatment goals for PM are to ameliorate or eliminate symptoms, make less their impact on activities and interpersonal relationships, and minimize adverse tenors of treatment. Although numerous treatment strategies are available, small in number have been adequately evaluated in randomized, controll trials. Furthermore, research findings can be difficult to apply because of the variability of inclusion criteria and issue measures in clinical trials, the lack of studies directly comparing treatment modalities, and the high rejoinder rate to placebo (25 to 50 percent) (23)

Initially, all patients with PM should be propounded nonpharmacologic therapy. (4) Medication should be exhibited to patients with persistent symptoms of PM and those who come up to face to face criteria for PMDD. Surgical treatment, principally hysterectomy plus bilateral oophorectomy, is controversial because it is irreversible and associated with significant risks. Surgery may be considered in sharply affected patients who fail to reply to other therapies and also have significant gynecologic question s for which surgery would be appropriate. (14)

NONPHARMACOLOGIC THERAPY

Nonpharmacologic interventions for PM include patient education, supportive therapy, and behavioral changes. (13) Women who have been educated about the biologic basis and prevalence of PM report an increased feeling of control and relief of symptoms. (4)

Although not rigorously evaluated, supportive therapy may be responsible for the high placebo-response rates in clinical trials. Small comparative trials (1412) exhibit some benefit for formal psychologic interventions of that kind as relaxation therapy and cognitive behavioral therapy. Behavioral measures include keeping a symptom diary, getting adequate tranquillity and exercise, and making dietary changes.